Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Phase 3

Completed

• Conditions: Small-cell Lung Cancer
• Interventions: Drug: Doxorubicin (DOX); Drug: Lurbinectedin (PM01183); Drug: Topotecan; Drug: Cyclophosphamide (CTX); Drug: Vincristine (VCR)

• Registration Number: NCT02566993
• Lead Sponsor: PharmaMar

Brief Summary

Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.

Detailed Description

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of an experimental arm consisting of PM01183/DOX combination followed by PM01183 alone, if applicable vs. best Investigator's choice between CAV or topotecan as a control arm, in SCLC patients who failed one prior platinum-containing line but no more than one prior chemotherapy-containing line.

Study Timeline

• Study First Submitted: 2015-09-24
• Study First Submitted QC: 2015-10-01
• Study First Posted: 2015-10-02
• Study Start: 2016-08-30
• Primary Completion: 2020-02-24
• Study Completion: 2020-02-24
• Status Verified: 2021-08
• Results First Submitted: 2021-08-06
• Results First Submitted QC: 2021-09-29
• Last Update Submitted: 2021-09-29
• Results First Posted: 2021-10-28
• Last Update Posted: 2021-10-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 613

Inclusion Criteria

1. Voluntary written informed consent
2. Adult patients ≥ 18 years
3. Histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ≥ 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in >50% of tumor cells.
4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2.
5. Adequate hematological, renal, metabolic and hepatic function within 7-10 days prior to randomization
6. At least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicity
7. Prior radiotherapy (RT): At least four weeks since completion of whole-brain irradiation, at least two weeks since completion of prophylactic cranial irradiation, and to any other site.
8. Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to six weeks after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product dose.

Exclusion Criteria

1. More than one prior chemotherapy-containing line(re-challenge with the same initial regimen is not allowed)

2. Patients who never received platinum-containing regimen for Small-cell Lung Cancer (SCLC)

3. Prior treatment with PM01183, topotecan or anthracyclines.

4. Limited-stage patients who are candidates for local or regional therapy

5. Impending need for palliative RT or surgery for pathological fractures and/or for medullary compression within four weeks prior to randomization.

6. Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization

7. Concomitant diseases/conditions:

   Angina, myocardial infarction, congestive heart failure or clinically significant valvular heart disease, arrhythmia, immunodeficiency (including known HIV seropositive), ongoing or treatment-requiring chronic liver disease, active infection, oxygen requirement within two weeks prior to randomization, diffuse interstitial lung disease (ILD) or pulmonary fibrosis, second invasive malignancy treated with chemotherapy and/or radiotherapy, invasive fungal infections requiring systemic treatment within 12 weeks of randomization.

8. Pregnant or breast feeding women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Arm 1	Doxorubicin (DOX)	CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
Experimental Arm	Lurbinectedin (PM01183)	Lurbinectedin (PM01183) / Doxorubicin
Control Arm 1	Cyclophosphamide (CTX)	CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
Experimental Arm	Doxorubicin (DOX)	Lurbinectedin (PM01183) / Doxorubicin
Control Arm 1	Vincristine (VCR)	CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
Control Arm 2	Topotecan	Topotecan

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS)	Every three months up to death or study termination, a period of approximately 3.5 years	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Secondary Outcome Measures

Name	Time	Method
Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Best Antitumor Response in Patients With Chemotherapy-free Interval <90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months	At 12 months	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Progression-free Survival (PFS) by Independent Review Committee	Every six weeks up to progression disease, a period of approximately 3.5 years	Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Progression-free Survival Rate at 6 Months by Independent Review Committee	At 6 months	Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Progression-free Survival Rate at 12 Months by Independent Review Committee	at 12 months	Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Best Antitumor Response by Independent Review Committee	Every three months up to death or study termination, a period of approximately 3.5 years	Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Duration of Response by Independent Review Committee	Every three months up to death or study termination, a period of approximately 3.5 years	Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days	Every six weeks up to progression disease, a period of approximately 3.5 years	Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months	At 18 months	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months	At 24 months	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Overall Response Rate by Independent Review Committee	Every three months up to death or study termination, a period of approximately 3.5 years	Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Overall Survival in Patients Without Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Overall Survival in Patients With Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Best Antitumor Response in Patients With Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days	Every six weeks up to progression disease, a period of approximately 3.5 years	Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Best Antitumor Response in Patients With Chemotherapy-free Interval ≥ 90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Overall Survival in Patients With Chemotherapy-free Interval < 90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline	Every six weeks up to progression disease, a period of approximately 3.5 years	Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Best Antitumor Response in Patients Without Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Duration of Response in Patients With Chemotherapy-free Interval <90 Days	Every three months up to death or study termination, a period of approximately 3.5 years	Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Duration of Response in Patients With Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Duration of Response in Patients Without Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Progression-free Survival in Patients With Central Nervous System Involvement at Baseline	Every six weeks up to progression disease, a period of approximately 3.5 years	Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Overall Response Rate in Patients With Central Nervous System Involvement at Baseline	Every three months up to death or study termination, a period of approximately 3.5 years	Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Trial Locations

Locations (160)

Alabama Oncology; 🇺🇸 Birmingham, Alabama, United States

Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers; 🇺🇸 Chandler, Arizona, United States

St Jude Hospital Yorba Linda dba St Joseph Heritage Healthcare; 🇺🇸 Fullerton, California, United States

Loma Linda University Medica! Center; 🇺🇸 Loma Linda, California, United States

Innovative Clinical Research Institute (ICRI); 🇺🇸 Whittier, California, United States

Boca Raton Regional Hospital Lynn Cancer Institute; 🇺🇸 Boca Raton, Florida, United States

Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center; 🇺🇸 Fort Lauderdale, Florida, United States

H. Lee Moffitt Cancer Center & Research Institute; 🇺🇸 Tampa, Florida, United States

Joliet Oncology-Hematology Associates, Ltd.; 🇺🇸 Joliet, Illinois, United States

Healthcare Research Network III, LLC; 🇺🇸 Tinley Park, Illinois, United States

Scroll for more (150 remaining)